GPRC5D,oricar-017
oricell therapeutics
['mmsm', 'car t']
similarly impressive early results from gprc5d-targeted oricar-017 with a cr/scr rate of 60%, with the study including patients with previous bcma car t, and all 10 patients progression-free to date #mmsm #tcellrx #asco22 
haematology registrar | evidence-based medicine | MPH @Harvard | health policy @PORTAL_research | physiology | musician | writer | @_futurethinkers cofounder